Increased circulating serum Ang-2 (sAng-2) concentrations or a shift in the sAng-1/sAng-2 ratio in favor of sAng-2 in tumor patients has been shown to correlate with advanced tumor progression and poor survival in epithelial ovarian cancer (Sallinen et al., 2014; Sallinen et al., 2010), melanoma (Helfrich et al., 2009), metastatic colorectal cancer (Goede et al., 2010), neuroendocrine tumors (Detjen et al., 2010), hepatocellular carcinoma (Bouattour, Payance & Wassermann, 2015) and pancreatic cancer (Schulz et al., 2011). This evidence concerns the gene ANGPT2 and melanoma.